Update on trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties.
Lin
J T
JT
Program of Developmental Therapy and Clinical Investigation, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Bertino
J R
JR
D000328:Adult; D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004351:Drug Resistance; D005260:Female; D005493:Folic Acid Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D016597:Trimetrexate
D000970:Antineoplastic Agents; D000981:Antiprotozoal Agents; D005493:Folic Acid Antagonists; D011799:Quinazolines; D016597:Trimetrexate